MedTrace Logo

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

NCT02419560 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-05-24

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal dosing scheme for the combination of ibrutinib with ABT-199 for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

Conditions

  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell

Interventions

DRUG

ABT-199 and Ibrutinib Combination

Both are administered orally once daily.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Craig Portell, MD

    lead OTHER

Principal Investigators

  • Craig A Portell, MD · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419560 on ClinicalTrials.gov